(2020) Pharmacological treatments of COVID-19. Pharmacological Reports. pp. 1446-1478. ISSN 1734-1140
Full text not available from this repository.
Abstract
The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies.
Item Type: | Article |
---|---|
Keywords: | COVID-19 Pharmacology Pneumonia SARS-CoV2 respiratory syndrome coronavirus host gene-expression corticosteroid treatment 2019-novel coronavirus rheumatoid-arthritis eculizumab treatment clinical-efficacy interferon-alpha sars ribavirin Pharmacology & Pharmacy |
Page Range: | pp. 1446-1478 |
Journal or Publication Title: | Pharmacological Reports |
Journal Index: | WoS |
Volume: | 72 |
Number: | 6 |
Identification Number: | https://doi.org/10.1007/s43440-020-00152-9 |
ISSN: | 1734-1140 |
Depositing User: | Mr mahdi sharifi |
URI: | http://eprints.ssu.ac.ir/id/eprint/30656 |
Actions (login required)
View Item |